My Cart

HLA-A*0201 | B2M | p53 (RMPEAAPPV)

Product Inquiry

HLA-A*0201 | B2M | p53 (RMPEAAPPV) Background

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (GLAPPQHLIRV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and GLAPPQHLIRV peptide of the p53.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics LlcDiabetic macular oedema; Geographic Atrophy; Macular Degeneration; Diabetic Retinopathy
Details
  • Product Inquiry
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland